Discontinue use if markedly elevated creatine kinase (>5 x ULN) occurs or ILD is suspected. Not to be used in patients w/ acute, serious condition suggestive of myopathy or predisposing to development of renal failure secondary to rhabdomyolysis eg, sepsis, hypotension, major surgery, trauma, severe metabolic, endocrine & electrolyte disorders or uncontrolled seizures. Predisposing factors for myopathy/rhabdomyolysis eg, hypothyroidism, history of hereditary muscular disorders or toxicity w/ another HMG-CoA reductase inhibitor or fibrate, situations where increased plasma levels occur. Risk factors for DM eg, fasting glucose 5.6-6.9 mmol/L, BMI >30 kg/m2
, raised triglycerides, HTN. Assess renal function during routine follow-up. Perform LFTs prior to & 3 mth following initiation. Patients w/ specific types of genetic polymorphisms increasing rosuvastatin exposure. Asian patients. Galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. Not recommended in combination w/ gemfibrozil. Concomitant use w/ ciclosporin, nicotinic acid, azole antifungals, PIs, macrolides. History of hepatic disease, excessive alcohol consumption. Severe renal impairment. Women of childbearing potential should use effective contraception. Childn <10 yr. Elderly >70 yr.